Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · Impax I

Impax Small Cap Fund Institutional Class (PXSIX)

Ticker PXSIX · · Holdings as of Jun 30, 2026

Expense ratio
0.91%$91/yr per $10k
5-yr return
+8.0%annualized
1-yr return
+11.7%as of Dec 2025
Net assets
$949.2Mall share classes
Holdings
62

Bottom line

Is PXSIX a good fund? The bottom line

PXSIX is the Institutional Class share class of Impax Small Cap Fund, a managed small-cap mutual fund from Impax I.

It charges 0.91% — about $91 a year on every $10,000 invested, cheaper than 59% of small-cap funds we track.

It returned +11.7% over one year, +8.0% a year over five years, +8.3% a year over ten (as of Dec 31, 2025, per its prospectus).

With $949 million in net assets and 62 holdings, its largest position is Ligand Pharmaceuticals, Inc. (5.1%) and the top 10 make up 30.7% of the portfolio.

What stands out

  • No front-end sales load

Updated Nov 19, 2026

What PXSIX invests in

The Small Cap Funds investment objective is to seek long-term growth of capital.

The Small Cap Fund follows a sustainable investing approach, investing in companies that the Adviser believes are well positioned to benefit from the transition to a more sustainable global economy, integrating a proprietary corporate resilience (Corporate Resilience) (formerly known as ESG) analysis that considers governance structures, the management of material environmental and social risks, climate risks (physical and transition), human capital management, and controversies (such analysis, Corporate Resilience Analysis) into portfolio construction and managing the portfolio within certain risk parameters (e.g., sector and regional exposure) relative to the Funds benchmark universe of Russell 2000 Index companies. The Fund utilizes the Impax Sustainability Lens, a proprietary tool designed to facilitate a systematic review of the economic opportunities and risks associated with the…

From the fund's prospectus (filed Apr 24, 2026).

PXSIX performance

Average annual total returns
1 yr5 yr10 yr
PXSIX+11.7%+8.0%+8.3%
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full PXSIX performance history →

What PXSIX costs

On a $10,000 investment, PXSIX's 0.91% expense ratio costs about $91 a year. The prospectus estimates $1,120 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full PXSIX fee table →

PXSIX top 10 holdings

#Holding% of fund
1Ligand Pharmaceuticals, Inc.5.08%
2Victory Capital Holdings, Inc.4.65%
3Eastern Bankshares, Inc.2.99%
4Mitek Systems, Inc.2.88%
5Neurocrine Biosciences, Inc.2.84%
6Acadian Asset Management, Inc.2.64%
7Teradata Corp.2.50%
8SI-BONE, Inc.2.45%
9Onto Innovation, Inc.2.35%
10Pinnacle Financial Partners, Inc.2.29%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 30.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to PXSIX

More funds like PXSIX →

PXSIX FAQ

What is the expense ratio of PXSIX?
PXSIX's expense ratio is 0.91%, which works out to about $91 a year for every $10,000 invested. The prospectus estimates total costs of $1,120 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is PXSIX a good investment?
It depends on your goals, but the data points to: no front-end sales load. This is general information, not personalized advice.
What does PXSIX hold?
PXSIX's largest holdings are Ligand Pharmaceuticals, Inc. (5.1%), Victory Capital Holdings, Inc. (4.6%), Eastern Bankshares, Inc. (3.0%), Mitek Systems, Inc. (2.9%), Neurocrine Biosciences, Inc. (2.8%). It holds 62 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is PXSIX's 5-year return?
PXSIX returned +8.0% a year over the five years ending Dec 31, 2025, and +8.3% a year over ten years. Past performance does not guarantee future results.
Does PXSIX have a sales load?
No. PXSIX has no front-end sales charge.
Who manages PXSIX?
PXSIX is offered by Impax I through Impax Funds Series Trust I.